Methodological issues in estrogen treatment trials for Alzheimer's disease.
Over the past two decades, many clinical trials have been conducted using different forms of estrogen therapy with and without progestin supplementation in an effort to treat diagnosed Alzheimer's disease. Design variations among these trials may account for the inconsistent results of these investigations and the persistent gap in knowledge about the appropriate use of estrogen in the treatment paradigm for degenerative diseases.
Mulnard
Ruth A
RA
Department of Neurology, Institute for Brain Aging and Dementia, 1113 Gillespie Neuroscience Research Facility, University of California-Irvine, Irvine, CA 92697-4540, USA. ramulnar@uci.edu
D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004958:Estradiol / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D010919:Placebos; D016032:Randomized Controlled Trials as Topic
D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D010919:Placebos; D004958:Estradiol